Charles Schwab’s CervoMed CRVO Stock Holding History

Charles Schwab’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,722	Closed	-$116K	–	3506
2025 Q1	$116K	Hold	12,722	–	–	﹤0.01%	3317
2024 Q4	$29.8K	Hold	12,722	–	–	﹤0.01%	3471
2024 Q3	$186K	Hold	12,722	–	–	﹤0.01%	3342
2024 Q2	$218K	Buy	+12,722	New	+$278K	﹤0.01%	3433
2021 Q2	–	Sell	-590	Closed	-$41K	–	3438
2021 Q1	$41K	Buy	+590	New	+$49.5K	﹤0.01%	3457

Other funds holding CRVO

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return

AAS

Avantax Advisory Services Dallas, Texas $18.2B AUM 15.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's CRVO Position: Q2 2025 in Review

Charles Schwab sold out of CervoMed (CRVO) in Q2 2025, closing a stake of 12,722 shares — an estimated $116K sold.

Charles Schwab first reported a position in CRVO in Q1 2021 and held it in 5 quarters. The position peaked at $218K in Q2 2024. 45 funds tracked by Wall St. Rank hold CRVO as of Q2 2025.

Charles Schwab reported no remaining CervoMed position as of Q2 2025 after selling out during the quarter.
Charles Schwab sold 12,722 CervoMed shares in Q2 2025, an estimated $116K.
Charles Schwab first reported a position in CervoMed in Q1 2021 and held it in 5 quarters.
Charles Schwab's CervoMed position peaked at $218K in Q2 2024.
45 funds tracked by Wall St. Rank held CervoMed as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.